IL161989A0 - Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure - Google Patents

Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Info

Publication number
IL161989A0
IL161989A0 IL16198902A IL16198902A IL161989A0 IL 161989 A0 IL161989 A0 IL 161989A0 IL 16198902 A IL16198902 A IL 16198902A IL 16198902 A IL16198902 A IL 16198902A IL 161989 A0 IL161989 A0 IL 161989A0
Authority
IL
Israel
Prior art keywords
treatment
reuptake inhibitors
norepinephrine reuptake
cognitive failure
cognitive
Prior art date
Application number
IL16198902A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL161989A0 publication Critical patent/IL161989A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL16198902A 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure IL161989A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (1)

Publication Number Publication Date
IL161989A0 true IL161989A0 (en) 2005-11-20

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16198902A IL161989A0 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Country Status (26)

Country Link
US (1) US20050009925A1 (de)
EP (1) EP1458368B1 (de)
JP (1) JP2005517647A (de)
KR (1) KR20040066895A (de)
CN (1) CN1713900A (de)
AU (1) AU2002352625A1 (de)
BR (1) BR0213581A (de)
CA (1) CA2467802A1 (de)
CO (1) CO5590907A2 (de)
CZ (1) CZ2004709A3 (de)
DE (1) DE60223718T2 (de)
EA (1) EA200400793A1 (de)
EC (1) ECSP045145A (de)
ES (1) ES2295435T3 (de)
HR (1) HRPK20040528B3 (de)
HU (1) HUP0402619A3 (de)
IL (1) IL161989A0 (de)
MX (1) MXPA04005716A (de)
MY (1) MY136367A (de)
NO (1) NO20042904L (de)
NZ (1) NZ532065A (de)
PL (1) PL369311A1 (de)
SK (1) SK2442004A3 (de)
TW (1) TW200300672A (de)
WO (1) WO2003049724A1 (de)
ZA (1) ZA200404274B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050049476A (ko) * 2002-08-14 2005-05-25 파마시아 앤드 업존 캄파니 엘엘씨 홍조를 치료하기 위한 레복세틴의 용도
ATE526954T1 (de) * 2003-07-28 2011-10-15 Leslie Joe Dunaway Atomoxetin zur behandlung von allergischer rhinitis und asthma
CA2530014A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
JP4185154B2 (ja) * 2004-04-30 2008-11-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害治療用の置換モルホリン化合物
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317731A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Hyperhidrosis treatment
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
EP2764863B1 (de) * 2011-10-03 2020-03-11 National Center for Geriatrics and Gerontology Tau-aggregationshemmer
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2962687B1 (de) 2013-04-02 2019-06-05 The Doshisha Tau-aggregationshemmer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
DE60022692T2 (de) * 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
WO2001027068A1 (en) * 1999-10-13 2001-04-19 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
WO2002053104A2 (en) * 2001-01-02 2002-07-11 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory

Also Published As

Publication number Publication date
CA2467802A1 (en) 2003-06-19
CN1713900A (zh) 2005-12-28
ECSP045145A (es) 2004-07-23
EP1458368A1 (de) 2004-09-22
TW200300672A (en) 2003-06-16
HUP0402619A3 (en) 2008-04-28
US20050009925A1 (en) 2005-01-13
NO20042904L (no) 2004-09-07
HUP0402619A2 (hu) 2005-03-29
BR0213581A (pt) 2004-08-24
EA200400793A1 (ru) 2004-10-28
ZA200404274B (en) 2005-09-13
DE60223718T2 (de) 2008-10-30
PL369311A1 (en) 2005-04-18
NZ532065A (en) 2007-03-30
MXPA04005716A (es) 2004-12-06
KR20040066895A (ko) 2004-07-27
ES2295435T3 (es) 2008-04-16
DE60223718D1 (de) 2008-01-03
JP2005517647A (ja) 2005-06-16
HRPK20040528B3 (en) 2006-03-31
CZ2004709A3 (cs) 2004-10-13
CO5590907A2 (es) 2005-12-30
EP1458368B1 (de) 2007-11-21
HRP20040528A2 (en) 2004-10-31
WO2003049724A1 (en) 2003-06-19
AU2002352625A1 (en) 2003-06-23
SK2442004A3 (en) 2004-12-01
MY136367A (en) 2008-09-30

Similar Documents

Publication Publication Date Title
PT1531819E (pt) Utilização de inibidores da i capa b cinase na terapia da dor
NO20035609L (no) Fremgangsmate for kontinuerlig naftabehandling
IL159347A0 (en) Arylamines for the treatment of conditions associated with gsk-3
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
NO20014047D0 (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
WO2004047830A3 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen
IL209319A0 (en) Substituted tetracycline compounds for the treatment of malaria
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
IL161989A0 (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
PL377552A1 (pl) Leczenie zespołu nadpobudliwości psychoruchowej z deficytem uwagi
IL162308A0 (en) Aminoindane derivatives as serotonin and norepinephrine uptakeinhibitors
EP1461030A4 (de) Aminoalkyl-benzofuran-5-ol-verbindungen zur behandlung von glaukom
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
SI1530462T1 (sl) 1-fenil-2-dimetilaminometicikloheksanske spojine za terapijo depresivnih simptomatik, bolečine in inkontinence
HK1069540A (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
GB2410744B (en) Kinase inhibitors for the treatment of disease
AU2003227521A1 (en) Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
IL162492A0 (en) Use of alkylphosphocholines for the preventative treatment of protozoandiseases
GB0212790D0 (en) Medicament for the treatment of diabetes
GB0224481D0 (en) Treatment of fluids